BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/2/2017 5:29:41 AM | Browse: 68 | Download: 79
Publication Name World Journal of Clinical Oncology
Manuscript ID 33104
Country of Manuscript Source Greece
Received
2017-02-06 16:28
Peer-Review Started
2017-02-10 17:02
To Make the First Decision
2017-03-27 11:17
Return for Revision
2017-03-28 14:41
Revised
2017-04-03 18:53
Second Decision
2017-04-14 11:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-04-24 10:08
Articles In Press
2017-04-24 10:08
Publication Fee Transferred
Edit the Manuscript by Languag Editor
Typeset the Manuscript
2017-05-26 04:54
Publish the Manuscript Online
2017-06-02 05:29
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript Type Review
Article Title Evolving role of Sorafenib in the management of hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Ioannis A Ziogas and Georgios Tsoulfas
Funding Agency and Grant Number
Correspondence To Georgios Tsoulfas, MD, PhD, FACS, Assistant Professor of Surgery, 1st Department of Surgery, Aristotle University of Thessaloniki, 66 Tsimiski Street, 56403 Thessaloniki, Greece. tsoulfasg@gmail.com
Keywords Sorafenib; Hepatocellular carcinoma; Liver neoplasm; Multikinase inhibitor; Targeted therapy; Tumor angiogenesis; Signaling pathways; Adjuvant therapy; Liver cancer; Liver transplantation; Liver resection
Core Tip Hepatocellular carcinoma (HCC) is an aggressive and invasive malignancy. Curative options, such as resection and liver transplantation, are limited to only a few patients, who are suitable candidates. Sorafenib is the only approved systemic treatment in HCC, especially for advanced tumor stage and early stage liver disease. Recent findings suggest that it may also be helpful in carefully selected decompensated patients. Its adjuvant role is yet to be proven with more promising results. The combination of Sorafenib with other chemotherapy agents has shown improved efficacy and safety. We aim to present the evolution of Sorafenib’s use over the last decade.
Publish Date 2017-06-02 05:29
Citation Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the ma¬nagement of hepatocellular carcinoma. World J Clin Oncol 2017; 8(3): 203-213
Url http://www.wjgnet.com/2218-4333/full/v8/i3/203.htm
DOI http://dx.doi.org/10.5306/wjco.v8.i3.203
Full Article (PDF) WJCO-8-203.pdf
Full Article (Word) WJCO-8-203.doc
Revised Manuscript 33104-Review.docx
Peer-review Report 33104-Peer-review(s).pdf
Answering Reviewers 33104-Answering reviewers.pdf
Scientific Misconduct Check 33104-Scientific misconduct check.pdf
Scientific Editor Work List 33104-Scientific editor work list.pdf
Audio 33104-Audio core tip.mp3
Conflict-of-Interest Statement 33104-Conflict-of-interest statement.pdf
Copyright Assignment 33104-Copyright assignment.pdf